Frequency Therapeutics (FREQ) Virtual R&D Event

Frequency Therapeutics (FREQ) Virtual R&D Event

Frequency Therapeutics (FREQ) will host a Virtual R&D Event for investors on Tuesday, November 9th from 8:00 am to 10:00 am EST. The program will include presentations by management, key opinion leaders and program executives who will provide detail on a broad range of pipeline advances for Frequency’s clinical-stage efforts in hearing restoration, plans for new FX-322 Phase 2 studies in sensorineural hearing loss, as well as its pre-clinical program for remyelination in multiple sclerosis.

 

Agenda (Partial)

  • Program update for FX-322, a regenerative drug candidate to treat sensorineural hearing loss (SNHL)
    • Detailed overview and insights from all data from clinical studies of FX-322
    • Overview of ongoing FX-322 clinical development program and strategy
    • Regulatory update and patient reported outcome measures
    • Hearing research and discovery programs and opportunities for pipeline expansion
  • Presentations by key opinion leaders
    • Sumit Dhar, PhD, Hugh Knowles Professor of Hearing Science and Associate Provost for Faculty at Northwestern University
    • Steven D. Targum, MD, Scientific Director, Signant Health, Consultant in Psychiatry, Mass General Hospital
  • Remyelination in multiple sclerosis
    • Overview of Frequency’s program for remyelination in multiple sclerosis
    • In vivo data and approach to target identification toward initiation of clinical trials
  • Q&A with management and key opinion leaders
    • David L. Lucchino, Chief Executive Officer
    • Peter Pfreundschuh, Chief Financial Officer
    • Carl LeBel, PhD, Chief Development Officer
    • Christopher Loose, PhD, Chief Scientific Officer
    • Kevin Franck, PhD, SVP, Strategic Marketing and New Product Planning
    • Susan Stewart, JD, LLM, Chief Regulatory Officer
    • Will McLean, PhD, SVP, Hearing Biology and Translational Research
    • Sanjay Magavi, PhD, VP, Myelination Research